Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (14)
  • Aurora Kinase
    (4)
  • Autophagy
    (13)
  • Bcr-Abl
    (51)
  • FLT
    (5)
  • PDGFR
    (8)
  • PROTACs
    (5)
  • Src
    (14)
  • c-Kit
    (12)
  • Others
    (50)
Filter
Search Result
Results for "Bcr-Abl" in TargetMol Product Catalog
  • Inhibitor Products
    112
    TargetMol | Activity
  • PROTAC Products
    21
    TargetMol | inventory
  • Isotope products
    4
    TargetMol | natural
  • Natural Products
    2
    TargetMol | composition
  • Recombinant Protein
    3
    TargetMol | Activity
BCR-ABL-IN-8
T829091808288-49-4
BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor featuring a trimethoxy group [1].
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
BCR-ABL-IN-4
T639322669790-59-2
BCR-ABL-IN-4 is a BCR-ABLL inhibitor that exhibits anticancer activity.BCR-ABL-IN-4 has an inhibitory effect on cancer cell growth and is able to act on K562 cells (IC50: 0.67 nM) and BCR-ABL T315I-transfected Ba/F3 cells (IC50: 16 nM).
  • $1,520
8-10 weeks
Size
QTY
PROTAC BCR-ABL Degrader-1
T77974
PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, promotes Bcr-Abl degradation through the ubiquitin-proteasome pathway and demonstrates antiproliferative effects on K562 cells, suggesting its utility in cancer research [1].
  • Inquiry Price
Size
QTY
BCR-ABL-IN-6
T634502499499-26-0
BCR-ABL-IN-6 (9h) is an imatinib derivative and a selective inhibitor of Bcr-Abl kinase that acts on Bcr-AblWT (IC50: 4.6 nM) and Bcr-AblT3151 (IC50: 277 nM). BCR-ABL-IN-6 (9h) was able to be used in the study of chronic myeloid leukemia treatment.
  • $1,520
6-8 weeks
Size
QTY
BCR-ABL-IN-7
T72958688050-42-2
BCR-ABL-IN-7 is a WT and T315I mutant ABL kinase inhibitor.BCR-ABL-IN-7 potently inhibits WT and T315I mutant ABL kinase activity.BCR-ABL-IN-7 can be used in chronic myelogenous leukemia (CML) research.
  • $30
In Stock
Size
QTY
BCR-ABL-IN-5
T633321795736-60-5
BCR-ABL-IN-5 is a Bcr-Abl (Breakpoint cluster region-Abelson) kinase inhibitor that acts on Bcr-AblWT (IC50: 0.014 μM) and Bcr-AblT3151 (IC50: 0.45 μM) and exhibits some anti-proliferative effects on leukemic cells. effect.
  • $1,520
6-8 weeks
Size
QTY
BCR-ABL-IN-3
T397322240191-12-0
BCR-ABL-IN-3 is a highly effective and irreversibly binding inhibitor of Bcr-Abl, displaying a remarkable potency with an IC50 value of ≤100 nM for Ba/F3 Bcr-Abl T3151. This compound exhibits significant anti-cancer activity.
  • $970
Backorder
Size
QTY
BCR-ABL-IN-2
T10489897369-18-5
BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I).
  • $1,520
6-8 weeks
Size
QTY
BCR-ABL-IN-1
T10488188260-50-6
BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.
  • $1,520
6-8 weeks
Size
QTY
LXH254
T118981800398-38-2
LXH254 is a potent C-Raf and B-Raf inhibitor.
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Hot
AN-019
T26625879507-25-2In house
AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.
  • $293 TargetMol
In Stock
Size
QTY
TargetMol | Inhibitor Sale
PF-06651481-00
T283741391063-17-4
PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.
  • $79
In Stock
Size
QTY
PPY A
T23182875634-01-8
PPY A is a potent inhibitor of T315l mutant and wild-type Abl kinase (IC50 of 9 and 20 nM, respectively).PPY A also inhibits the growth of Bcr-Abl T315l mutant or wild-type Bcr-Abl genetically transformed cells.
  • $158
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Vamotinib
T637461416241-23-0In house
Vamotinib (PF-114) is an orally active and specific tyrosine kinase inhibitor with antiproliferative and antitumour activity.Vamotinib inhibits the phosphorylation of BCR/ABL and BCR/ABL-T315I, which promotes apoptosis. Vamotinib is used to study drug-resistant Philadelphia chromosome-positive (Ph+) leukaemia and Alzheimer's disease.
  • $133
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Imatinib Mesylate
T1621220127-57-1
Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR, respectively).
  • $54
In Stock
Size
QTY
TargetMol | Citations Cited
Bosutinib
T0152380843-75-4
Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.
  • $37
In Stock
Size
QTY
TargetMol | Citations Cited
Degrasyn
T6300856243-80-6
Degrasyn (WP1130) (WP1130), a specific deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor, also inhibits Bcr/Abl, which is a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).
  • $58
In Stock
Size
QTY
TargetMol | Citations Cited
Bafetinib
T6311859212-16-1
Bafetinib (INNO-406) (INNO-406) is an effective and specific dual Bcr-Abl/Lyn inhibitor (IC50: 5.8/19 nM), and no inhibition of the phosphorylation of the T315I mutant and less effective to c-Kit and PDGFR.
  • $31
In Stock
Size
QTY
TargetMol | Citations Cited
Dasatinib monohydrate
T1448L863127-77-9
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.
  • $33
In Stock
Size
QTY
TargetMol | Citations Cited
AT9283
T3068896466-04-9
AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).
  • $39
In Stock
Size
QTY
TargetMol | Citations Cited
Ponatinib
T2372943319-70-8
Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively).
  • $50
In Stock
Size
QTY
TargetMol | Citations Cited
Asciminib
T51771492952-76-7
Asciminib (ABL001) (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5–0.8nM).
  • $57
In Stock
Size
QTY
TargetMol | Citations Cited
Nilotinib
T1524641571-10-0
Nilotinib (AMN107) is a second-generation Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
  • $35
In Stock
Size
QTY
TargetMol | Citations Cited
Imatinib
T6230152459-95-5
Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit with oral activity. Imatinib has antitumor activity for the treatment of chronic granulocytic leukemia.
  • $36
In Stock
Size
QTY
TargetMol | Citations Cited
Nocodazole
T280231430-18-9
Nocodazole (Oncodazole) is a reversible inhibitor of microtubule polymerization and an inhibitor of Bcr-Abl. Nocodazole has antitumor activity, blocks the cell cycle and induces apoptosis.
  • $31
In Stock
Size
QTY
TargetMol | Citations Cited
Dasatinib
T1448302962-49-8
Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive. Dasatinib has antitumor activity and is used in the treatment of leukemia and lymphoma.
  • $37
In Stock
Size
QTY
TargetMol | Citations Cited
Rebastinib
T26401020172-07-9
DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT3, KDR, and Tie-2, and low activity to c-Kit. Rebastinib aimed at the Angiopoietin2-Tie2 pathway.
  • $40
In Stock
Size
QTY
TargetMol | Citations Cited
Carboxyamidotriazole Orotate
T14871187739-60-2
Carboxyamidotriazole Orotate (L-651582 Orotate) is a cytostatic inhibitor of non-voltage-operated calcium channels and calcium channel-mediated signaling pathways. Carboxyamidotriazole Orotate (L-651582 Orotate) is the orotate salt form of Carboxyamidotriazole (CAI), an orally bioavailable signal transduction inhibitor that in vitro has been shown to possess antileukaemic activities. Carboxyamidotriazole Orotate shows anti-tumor, anti-inflammatory, and antiangiogenic effects.
  • $67
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Multi-kinase inhibitor 1
T4191778274-97-8
Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.
  • $33
In Stock
Size
QTY
TargetMol | Inhibitor Sale
AKE-72
T806762566525-18-4
AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.
  • $195
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Bafetinib (INNO-406)
T22597
Bafetinib is a potent and selective dual inhibitor of Bcr-Abl/Lyn tyrosine kinase (IC50: 5.8nM and 19nM, respectively).
  • $72
Backorder
Size
QTY
TargetMol | Inhibitor Sale
BV02
T60081292870-53-2
BV02 is an inhibitor of 14-3-3 protein-protein interactions and can be used in studies about the treatment of chronic myeloid leukemia. BV02 disrupts hematopoietic cells expressing the IM-resistant T315I mutation and the IM-sensitive wild-type Bcr-Abl.
  • $36
In Stock
Size
QTY
TargetMol | Inhibitor Sale
HG-7-85-01
T386531258391-13-7
HG-7-85-01 is a type II ATP competitive inhibitor targeting wild-type and gatekeeper mutations forms of Bcr-Abl, PDGFRα, Kit, and Src kinases. It effectively inhibits T315I mutant Bcr-Abl kinase, as well as KDR and RET kinases with IC50 values of 3 nM, 20 nM, and 30 nM, respectively. In contrast, HG-7-85-01 exhibits weak or no inhibition towards other kinases (IC50 >2 μM). Furthermore, this compound inhibits cell proliferation through the induction of apoptosis and by impeding cell-cycle progression.
  • $970
Backorder
Size
QTY
TargetMol | Inhibitor Sale
AKI603
T643381432515-73-5
AKI603 is a novel small molecule inhibitor of Aurora kinase A (AurA)(IC50 = 12.3 nM). AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells[1][2].
  • $116
In Stock
Size
QTY
TargetMol | Inhibitor Sale
SIAIS178
T129072376047-73-1
SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).
  • $166
Backorder
Size
QTY
TargetMol | Inhibitor Sale
Imatinib-d8
T116401092942-82-9
Imatinib D8 is a deuterium-labeled Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that inhibits BCR/ABL, PDGFR, v-Abl, and c-kit kinase activity.
  • $372
5 days
Size
QTY
TargetMol | Inhibitor Sale
ML 2-23
T79081
ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].
  • Inquiry Price
Size
QTY
SIAIS100 TFA
T77969
SIAIS100 TFA is a potent BCR-ABL PROTAC degrader, exhibiting a DC50 of 2.7 nM. It is utilized in the research of chronic myeloid leukemia (CML) [1].
  • Inquiry Price
Size
QTY
DB07107
T15056552332-71-5
DB07107 is a potent inhibitor of drug resistant T315I mutant Bcr-Abl tyrosine kinase and a potent Akt1 inhibitor (IC50: 360 nM).
  • $1,520
6-8 weeks
Size
QTY
HS-438
T275551430720-10-7
HS-438 inhibits imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
  • $1,520
6-8 weeks
Size
QTY
Imatinib Impurity E
T739731365802-18-1
Imatinib Impurity E is a specific impurity found in Imatinib, an orally available inhibitor of multiple tyrosine kinases, including BCR/ABL, v-Abl, PDGFR, and c-kit. Imatinib (STI571) operates by semi-competitively inhibiting enzyme activity; it binds adjacent to the ATP binding site, inducing a closed or self-inhibited conformation [1] [2] [3] [4]. Additionally, Imatinib acts as an inhibitor against SARS-CoV and MERS-CoV [5].
  • Inquiry Price
Size
QTY
BVB-808
T713131180158-99-9
BVB-808 is a selective Jak2 type 1 inhibitor. Janus kinases are critical components of signaling pathways that regulate hematopoiesis. Mutations of the non-receptor tyrosine kinase JAK2 are found in many BCR-ABL-negative myeloproliferative neoplasms. Preclinical results support that JAK2 inhibitors could show efficacy in treating chronic myeloproliferative neoplasms. JAK2 has also been postulated to play a role in BCR-ABL signal transduction. Therefore, inhibitors of JAK2 kinases are turning into therapeutic strategies for treatment of chronic myelogenous leukemia (CML).
  • $1,520
6-8 weeks
Size
QTY
AST 487
T4053630124-46-8
AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.
  • $31
In Stock
Size
QTY
TargetMol | Citations Cited
Mcl1-IN-9
T119771810769-31-3
Mcl1-IN-9 is a potent myeloid cell leukemia-1 (Mcl-1) Inhibitor with an IC50 of 446 nM in reengineered BCR-ABL+ B-ALL cells and a Ki of 0.03 nM.
  • $1,670
6-8 weeks
Size
QTY
BGG463
T4618890129-26-7
BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respectively.
  • $56
In Stock
Size
QTY
TargetMol | Citations Cited
CT-721
T108971388710-60-8
CT-721 is a potent and time-dependent Bcr-Abl kinase inhibitor with an IC50 of 21.3 nM against wild-type Bcr-Abl kinase and has anti-chronic myeloid leukemia (CML) activity.
  • $1,970
8-10 weeks
Size
QTY
Bosutinib hydrate
T63875918639-08-4
Bosutinib hydrate (SKI-606 hydrate) is an orally active and potent dual kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of Philadelphia Chromosome Positive Chronic Granulocytic Leukemia.
  • $33
In Stock
Size
QTY
Imatinib D4
T116391134803-16-9
Imatinib D4 is a deuterium-labeled Imatinib. Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, PDGFR, v-Abl, and c-kit kinase activity.
  • $197
5 days
Size
QTY
PD173955
T3063260415-63-2
PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC.
  • $62
In Stock
Size
QTY
Dasatinib hydrochloride
T22303854001-07-3
Dasatinib hydrochloride (BMS-354825 HCl) (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib hydrochloride hydrochloride also induces Apoptosis and Autophagy.
  • $38
In Stock
Size
QTY
Cinnamaldehyde
T4S1551104-55-2
1. Cinnamaldehyde (Cinnamic Aldehyde) has antipyretic activity. 2. Cinnamaldehyde is a sedative agent. 3. Cinnamaldehyde inhibits invasive capabilities of MDA-MB-435S cells was correlated with down-regulating the expression of miR-27a. 4. Cinnamaldehyde induces the generation of reactive oxygen species and exerts vasodilator and anticancer effects. 5. Cinnamaldehyde appears to be a promising candidate as an adjuvant in combination therapy with 5-fluorouracil (5-FU) and oxaliplatin (OXA), two chemotherapeutic agents used in CRC treatment. The possible mechanisms of its action may involve the regulation of drugmetabolizing genes. 6. Cinnamaldehyde plays a certain role in inhibiting the occurrence and progression of melanoma and its action mechanism may be manifested by inhibiting expression of VEGF and HIF-α, thus blood vessel simulation and formation of new blood vessels of melanoma cells, and growth of tumors accordingly.
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited